【生物医药公司扎堆“赶考”港交所，“A+H”上市模式受青睐】2026年至今，港交所共有17家生物医药公司上市，占当期新股总数量105家的16.19%，合计募资185.01亿港元；同时，年内已有110家生物医药公司递表港交所，覆盖肿瘤、CGT、核药、眼科药物、医疗器械等热门赛道。此轮上市热潮中两大趋势尤为明显：一是多家A股药企跑步入场，争相构建“A+H”双资本平台；二是不少企业反复递表，甚至“四闯港交所”，高比例重复申报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.